Clinical Trial: Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07403552) titled 'Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants' on Jan. 26.

Brief Summary: The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.

Study Start Date: Jan. 31

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: DRUG: NSHO-101

Dose form - tablet Route of administration - oral Regimen / Treatment period - QD for 14 days

Recruitment Status: RECRUITING

Sponsor: Ensho Therapeutics, Inc.

Disclaimer: Curated by HT Syndication....